Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System

Bilal Haider Shamsi†, Mahanand Chatoo†, Xiao Kang Xu¹, Xun Xu³ and Xue Qun Chen¹,²*

¹ Department of Neurobiology, Department of Neurology of the Second Affiliated Hospital, School of Brain Science and Brain Medicine, Hangzhou, China, ² National Health Commission (NHC) and Chinese Academy of Medical Sciences (CAMS) Key Laboratory of Medical Neurobiology, Ministry of Education (MOE), Frontier Science Center for Brain Research and Brain Machine Integration, School of Brain Science and Brain Medicine, Zhejiang University, Hangzhou, China, ³ College of Renji, Wenzhou Medical University, Wenzhou, China

Somatostatin (SST) and somatostatin receptors (SSTRs) play an important role in the brain and gastrointestinal (GI) system. SST is produced in various organs and cells, and the inhibitory function of somatostatin-containing cells is involved in a range of physiological functions and pathological modifications. The GI system is the largest endocrine organ for digestion and absorption, SST-endocrine cells and neurons in the GI system are a critical effector to maintain homeostasis via SSTRs 1-5 and co-receptors, while SST-SSTRs are involved in chemo-sensory, mucus, and hormone secretion, motility, inflammation response, itch, and pain via the autocrine, paracrine, endocrine, and exoendocrine pathways. It is also a power inhibitor for tumor cell proliferation, severe inflammation, and post-operation complications, and is a first-line anti-cancer drug in clinical practice. This mini review focuses on the current function of producing SST endocrine cells and local neurons SST-SSTRs in the GI system, discusses new development prognostic markers, phosphate-specific antibodies, and molecular imaging emerging in diagnostics and therapy, and summarizes the mechanism of the SST family in basic research and clinical practice. Understanding of endocrines and neuroendocrines in SST-SSTRs in GI will provide an insight into advanced medicine in basic and clinical research.

Keywords: somatostatin, somatostatin receptor, inflammation response, enteric nervous system, gastrointestine (GI)

INTRODUCTION

Somatostatin (SST-14,28) is considered a universal endocrine molecule and a peptide hormone in the central nervous system (CNS), peripheral nervous system (PNS), and enteric nervous system (ENS) (1–5). It inhibits via different subtypes of SST receptors, and belongs to the superfamily of G protein-coupled receptors (GPCR) with 7-transmembrane domains. There are five SST receptors (SSTR1-5 and two isoforms SSTR2A, 2B), which are broadly expressed in the brain, spinal cord, dorsal root ganglion (DRGs), and ENS (1–6). The gastrointestinal (GI) system is recognized to be...
the largest endocrine organ for digestion and absorption by exocrine, endocrine, paracrine, and autocrine secretory effects in animals during GI physiological and pathophysiological processes. There are various SST-endocrine-cells embedded in the GI tract, which release gastrointestinal hormones to regulate GI function, such as SST producing-D cells from the stomach, intestine, and pancreas. SST in the GI system is involved in the inhibition of secretory activity and intestinal motility, blood flow, inflammation response, conduction of pain and sensation, and modulation of the release of hormone factors and other neurotransmitters, while SST-SSTRs mediate the release of gastric juice, intestinal juice, gastric acid, and other hormones via other endocrine factors (7–9). In addition, SST-SSTRs in non-GI tracts also are involved in digestion and absorption functions, such as the pancreas, liver, and gallbladder (10–12). The pancreas, containing SST producing-D cells, secretes the larger number of digestive liquids with digestive enzymes to mediate digestion and the absorption process. SST-SSTRs play an important role in the GI system via the neuroendocrine system. SST release from the GI is controlled by the vagus nerve and various local ENS neurotransmitters (13). SST-SSTRs of the brain and pituitary also impact on GI function via SST-SSTRs in the brain-gut axis and circulatory blood (14, 15). Advanced agonists and antagonists of SST-SSTRs are most commonly used in basic research and clinical practice (6, 16, 17), but the underlying mechanism is not fully understood. This mini-review will focus on the versatile functions of SST-SSTRs in the gastrointestinal system, and specifically in current advanced medicine.

**SST AND SSTRs IN GASTROINTESTINAL SYSTEM**

SST and SSTRs are widely distributed in the GI system of the GI tract and non-GI tract (Table 1), while major endocrine cells (Enteric endocrine cells, EEC) and D cells in the stomach, intestine, and pancreas produce SST (7, 10). 90% of SST cells in the GI tract are endocrine cells, while 10% are neurons in the ENS (5). SST-SSTRs have an inhibition effect on the physiological functions of digestion and absorption in the GI system (8, 9). SST release from the pituitary and SST in circulatory blood could modulate GI function via its receptors.

**SST-ENTERIC ENDOCRINE CELLS AND NERVOUS SYSTEM IN THE GASTROINTESTINAL TRACT**

In the stomach, there are parietal cells, chief cells, neck mucous cells, G cells (Gastrin), delta (D) cells (Somatostatin), X cells (Ghrelin), and enterochromaffin-like cells (ECL, Histamine) for chemical digestion. SST is secreted mainly by delta cells of gastric mucosa. Closed-type SST-D-cells in corpus inhibit parietal cells, ghrelin cells, and ECL cells, and open-type SST-D-cells in antrum inhibit gastrin (G) cells and chief cells via paracrine inhibition. In SST transgenic mice, SST secretion from SST-D-cells is regulated by hormones, neurotransmitters, neuropeptides, and metabolites (17). In SST-cre mice, many signaling receptors of peptide YY (PYY), gastric inhibitory polypeptide receptor, cholinergic receptor muscarinic 4, calcitonin receptor-like receptor, trace amine receptor 1, and calcium-sensing receptor (Casr) are identified and highly enriched in SST-D-cells in the gastric epithelium by transcriptomic analysis (17, 33). SSTR2 is expressed on endocrine cells and intramural, myenteric, and mucosal nerve fibers, while SSTR1 and 3 are mainly distributed on smooth muscles and neuronal cells of submucosal and myenteric ganglia; these ganglia also contain SST+ neurons (5). 5-hydroxytryptamine (5-HT) is a marker for EEC of the GI mucosa; small proportions of 5-HT cells also containing gastrin or SST can be found in the stomach, and glucagon-like peptide

**TABLE 1 | Distribution of SST and SST receptors in the gastrointestinal system.**

| Organ          | Cell/Tissue       | Humoral       | SST  | SSTR  | References |
|----------------|-------------------|---------------|------|-------|------------|
| Salivary gland | S.P and M.P       | Saliva        | +    |       | (18)       |
| Oesophagus     | S.P and M.P       | Gastric juice | ++  | +     | (5, 19)    |
| Stomach        | S.P               | Gastric juice | ++  | ++    | (5, 8, 9, 20–22) |
| D cells        |                   | Intestine juice | ++ | +     | (5, 20) |
| Small intestine| S.P               | Intestine juice |     |       |            |
| M.P            |                   |               | ++  |       |            |
| EEC            |                   |               |     |       |            |
| Large intestine| S.P               |               | +   |       | (5, 20, 22) |
| M.P            |                   |               | +   |       |            |
| D cells        |                   |               | +   |       |            |
| Liver          | Gallbladder       |               | +   |       | (11, 12, 23) |
| Pancreas       | D cells           | Pancreatic juice | +  |       | (24, 25) |
| Cilia          |                   |               |     | +     |            |
| Brain (Pituitary)| somatotropin cell |               |     |       | (26–28) |
| Blood vessels  | smooth muscle cell | Circulatory blood | +  |       | (15, 29) |
| Spinal dorsal horn (R4) | DRG |               | +   |       | (18, 30–32) |

S.P, submucosal plexus; M.P, myenteric plexus; + expression; - not reported; EEC, enteroeendocrine cell; DRG, dorsal root ganglion.
(GLP-1) or SST in the large intestine (34). SST-positive (SST+) neurons in the ENS are changed in pig diabetes model (Streptozotocin); SST+ neurons increased only in the submucosal plexus in corpus of the stomach, and in the myenteric and submucosal plexus in all segments of the small intestine, but SST+ neurons decreased in the descending colon (20). In female pig stomach, SST+ immuno-reactive neurons in the prepyloric area were increased in gastritis model (Aspirin, orally, 100mg/kg), in hyperacidity model (0.25MHCl intragastrically, 5ml/kg), and partial stomach resection model (21). Deletion of SST in multiple endocrine neoplasia type 1 (MEN-1) null mice caused hypergastrinemia and gastric carcinoids (35). After 12 ws-15% fructose in drinking, SST-D-cells were diminished in gastric corpus and increased in the antrum in male-Wistar rats (36). C-X-C motif chemokine ligand-14 (CXCL14) immunostaining endocrine cells and SST+ cell and nerve fibers co-expressed at the lamina propria and submucosal and muscular layer from the stomach to rectum in mice (37). This indicated that the mechanism of SST might involve immune function and inflammation response and crosstalk. There is localization of muscarinic acetylcholine receptors (M4) on D-cells in the mice stomach, and serum SST levels in M4-KO mice were higher than WT-mice; the activation of M4-receptors inhibits SST release from D-cells and minimizes SST inhibition for gastric acid release through SSTR2, which in turn enhances acid response by M3-receptors on parietal cells (38). In pig stomach tissues, the study demonstrated amino acids can increase gastrin and SST secretion, and the Casr-dependent pathway modulated H+\'-K+\'-ATPase activity (39).

In the small intestine, SST-D-cells are located in the lamina propria and between the epithelial cells of the crypts, while the SST+ neurons are located in the submucosal and myenteric plexus and innervate intestinal smooth muscles, submucosal layer, and the mucosa. SST+ neurons are type-II-Dogiel cells with branched dendrites and one long axon (5, 7). EEC expressed urotensin 2B in the jejunum and colon; these cells exhibitGLP-1 secretion through SSTR5 in a paracrine manner (40, 41). Occasionally SST-cells will colocalize with 5-HT in mice small intestine (34). The transcription factor “aristaless-related homeobox” (Arx) is specifically expressed in intestinal endocrine cells. In neonatal Arx-KO mice, many intestinal hormones, such as cholecystokinin, secretin, neurotensin, glucose dependent insulinotrophic peptide, GLP-1, and GLP-2, did not express in GI, but SST and chromogranin A (CGA) were significantly upregulated in the duodenum. Also there is loss of lipid transport in duodenal enterocytes, more lysozyme-positive Paneth cells, and increased-antimicrobial peptides in the steatorrhea mice (42). In mouse constipation model (Carbon bioactivated), Lactobacillus fermentum CQPC03 (LF-CQPC03) relieved constipation symptoms in mice, and serum levels of SST were lower, and levels of gastrin, endothelin, and acetylcholinesterase were higher in mice after CQPC03 treatment (43). In arthritic-rats (Curcumin,100mg/kg, oral), SST secretion elevated from the endocrine cells in the small intestine, and SST exhibited an anti-arthritic effect via cAMP/PKA and Ca2+/CaMKII mechanism. SST depletor (CSH) and non-selective SST receptor antagonist (C-SOM) abolished the inhibitory effect of curcumin on arthritis (44), this supported the hypothesis that SST from GI mediates the inflammation response. In hereditary transthyretin amyloidosis patients undergoing evaluation for liver transplantation, SST (Octreotide) administration induced fasting motility with more daytime phase III migrating motor complexes, and higher frequency of low-amplitude complexes in 24h duodenoojunal manometry; there was a delay in SST (Octreotide) response in late-onset patients (50 years of age) (45).

In guinea pig large intestine, round or oval SST-neurons in the submucous plexus have oral projections, and in myenteric plexus both have oral and caudal projections. SST-neurons in the proximal colon are more abundant in the submucosal plexus as compared to the myenteric plexus, and in the distal colon myenteric plexus SST-neurons are denser and have visible varicosities. Two types of SST-neurons have been identified in pig: type-V descending interneurons located in the myenteric and outer submucosal plexus and type-IV neurons secretomotor neurons in all types of intramural plexuses (5). In the colon, there was a lower number of epithelium SST-cells in colitis (Dextran-sulfate-sodium-induced) rat model and higher epithelium SST-cells in colitis (Trinitrotoluene sulfonic acid) rat model (46, 47). In colitic-mice, SST (Octreotide) stimulated colonic sodium/hydrogen exchanger 8 (NHE8) expression, while SSTR2 agonist (Seglitide) and 5 agonist (L-817/818) restored NHE8 expression via by suppressing ERK1/2 phosphorylation (48). SST expression (LS174T-cells) stimulated colonic MUC2-mucin2 expression and mucus secretion in human goblet-like cells, this was blocked by SSTR5 siRNA transfection and SSTR5 antagonist (L817/818) (49). Colon tissue from selenoprotein glutathione peroxidase 2 (GPx2) knockout mice, under selenium deficiency or adequate Se supplementation, showed a downregulation of SST mRNA expression (50). GPx2 might be important for intestinal epithelium function. By single cell transcriptomic profiling from the colon, seven EEC subgroups were identified, four clusters expressed high levels of Tph1 (ECM-cells, 50%), two clusters were enriched for proglucagon (GCG) and PYY (L-cells, 40%), and the last cluster expressed high levels of SST, which is characteristic of D-cells (10%) (51). After change in dietary habits in irritable bowel syndrome (IBS) patients, there was an increase in SST-cells in the rectum epithelium and symptomatic relief (52, 53). Oral treatment (Lactobacillus plantarum ys2) in carbon-induced constipation Kunming mice reduced serum SST level, promoted gastrointestinal peristalsis, and reduced the first black stool defection time (54). SST immunoreactive neurons co-expressed with P2X1-receptor (ATP receptor) was detected in mouse myenteric and submucosal plexuses (55). Using intrinsic markers targeting vagal and spinal sensory, sympathetic, and parasympathetic axons, the spatiotemporal map showed extrinsic axons project along the myenteric plexus and keep intimate contact with enteric neurons in whole gut in mice E9.5-E16.5 (56). This proposed that SST-neurons can crosstalk with other neurotransmitters in the parasympathetic and sympathetic system and ENS of the gastrointestinal tract.
**SST-ENDOCRINE CELLS IN NON-GASTROINTESTINAL TRACT**

Somatotropes in the pituitary control GI function via brain-gut axis and circulation. Classical SST and growth hormone-releasing-hormone receptor (GHRH) in the hypothalamus affects negative and/or positive control growth hormone (GH) transcription and release in mammals. Currently, the structural and functional connection between Pomp-neurons and the somatotrophic hypothalamo-pituitary axis have been reported in larval zebrafish. Excessive feeding induced leptin resistance and decreased-Pomc expression; Pomp-neurons stimulating SST-neurons result in reduced-growth hormone. So, SST-neurons mediate faster somatic growth, this suggests that a Pomc-SST-GH axis might be involved in metabolism and homeostasis (57). Both SSTR2 and SSTR4 in the hippocampus selectively inhibit HPA axis activation induced by stress but regulate antidepressive and anti-anxiety effects through different mechanisms in rats (26). SSTR5 modifies HPA axis stress response and attenuates corticotropin responses to corticotropin releasing factor (CRF) by post-transcriptionally suppressing CRFR1 expression and function via miR-449 (27). In pituitary AtT20-cells, CRF (100nM) induced rapid Rab10-dependent resurfacing of endocytosed SSTR2 via CRFR1, providing a feedback mechanism to inhibit CRFR signaling (28). Hypoxia stimulated expression of SSTMrna and protein in the periventricular nucleus of the hypothalamus and decreased GH release from pituitary and body weight gain in rat. CRFR1 and SST were involved in downregulated-mRNA of pituitary GH and upregulated-mRNA of hepatic insulin-like growth factor-I (58–61). The activation of central SST signaling induced a robust stimulation of food and water intake via SSTR2. Brain SST contributes to the orexigenic and dipsogenic responses during the dark-phase in rodents (62). SST released from the capsaicin-sensitive sensory nerves mediates analgesic and anti-inflammatory effects via the SSTR4-receptor, while orally novel SSTR4 agonists exert a potent anti-hyperalgesic effect in chronic neuropathy mice model (30).

In addition, SST, secreted by pancreatic D-cells (δ-cells), is a powerful paracrine inhibitor for insulin and glucagon secretion (from α-cells and β-cells). D-cells comprise only ~5% of the cells of the pancreatic islets. Some factors (Insulin, Glucagon, Urocortin 3, and GABA) released by neighboring α-cells or β-cells amplify the glucose-induced effects on SST secretion from D-cells, and SST acts locally within the islets as a paracrine or autocrine inhibitor of insulin (10). Glucose stimulates SST secretion in δ-cells via cAMP-dependent [Ca^{2+}]i release (63). SST-D-cells contain ATP-sensitive K+ channels which close at high glucose levels; this closure channels initiate membrane depolarization and increase SST secretion (63). Meanwhile, stimulation of SST secretion also depends on sodium/glucose cotransporter 2 (SGLT2), by which insulin can inhibit glucagon release by an indirect paracrine mechanism (64). After the ablation of insulin-secreting β-cells in mice, some glucagon-producing α-cells and SST-producing D-cells become insulin-expressing cells (65). α-cells can reprogram to produce insulin from puberty through to adulthood to aged individuals, even a long time after β-cell loss in mice, whereas only juvenile’s SST-producing-D-cells convert to insulin producer by dedifferentiation, proliferation, and re-expression of developmental regulators [FoxO1 (Forkhead box protein O1) and downstream effectors] (24). The multiple intra-islet cell interconversion mechanisms offer new insight for future clinical therapy. Reduced SST secretion in isolated islets induced hypersecretion of glucagon in high fat diet-fed female mice, however, this cannot be suppressed by exogenous SST (SST-14, 1.34mL/min/mg pancreas) (66). Cilia in pancreatic tissues are hubs for cellular signaling and are involved in proper development of pancreatic epithelium and β-cell morphogenesis via SSTR3. A paracrine negative feedback role for β-cell ciliary SSTR3 regulates insulin secretion. Immunohistochemical and electron microscopic study found abundant SSTR3-expressing solitary cilia in insulin- and GH-secreting cells in mouse. SSTR3 was restricted to the plasma membrane of cilia, but not at the cell body. The primary cilia in the islet-cells were longer than those in the pituitary cells and extended for a long distance in the intercellular canalculus endowed with microvilli (25). The study demonstrated the mechanisms of tight glycemic control in islet-D-cells, mice urocortin-3 co-released with insulin, and increased glucose-stimulated SST secretion via coge receptors, this indicated SST-dependent negative feedback control of insulin secretion (67).

**MECHANISMS OF SST–SSTRs IN ENDOCRINE CELLS**

SST is a cyclic hormone-release inhibitory peptide with 2-3 minutes half-life that has high binding affinity to all of its five SST-receptors (SSTRs) in the GPCR superfamily. SST negatively regulates the release of multiple hormones and cell proliferation via activation of its cognate receptors. The five subtypes of SSTR1-SSTR5 are coupled with inhibitory G protein Gi/o (Table 2) and are involved in motility, mucous and hormone secretion, blood vessels contractility, inflammation responses, and microbiotal flora (9, 54). Phosphorylation and dephosphorylation of SSTRs at C-terminal or serine and/or threonine residues is involved in fine-tuning signalling (75). A novel higher selective monoclonal antibody for extracellular domain of SSTR2 binds the surface of neuroendocrine tumor (NET) cells via signalling cascades and reduce tumor growth. Phosphosite-specific antibodies for human SSTR2 and SSTR5 monitor the spatial and temporal dynamics of SSTRs’ phosphorylation and dephosphorylation (75, 80). Based on the integrated physiological regulation mechanism of the neuroendocrine system, a high combination of chimeric molecules for NET and cancer have emerged (73, 81) in 2D- and 3D-cultures. SST-D2R multi-receptor targeting drugs inhibit CgA and serotonin secretion, but not NET cell growth (81). Overexpressed-SSTR2 in pancreatic human NETs demonstrated...
that fluorescence of SSTR2 receptor-mediated uptake was observed at the macro-, meso-, and microscopic scales, thus displaying specific SSTR2-digital image pathological findings, such as tumor boundaries and location (82).

### SST-SSTRs IN BASIC RESEARCH AND CLINICAL MEDICINE

SST analogues (Octreotide, Lanreotide, and Pasireotide (for SSTR2,5)) are widely used as first-line treatment for perioperative period, metabolic diseases, and tumor control (68, 78, 83). Octreotide, lanreotide, and pasireotide are applied to acromegaly, Cushing’s syndrome, and carcinoid syndrome, respectively (69, 70, 74). SST (Pasireotide 10-30mg/4ws/year) decreased urinary free cortisol and late-night salivary cortisol to normal levels in patients with Cushing’s disease (19). NETs are heterogeneous malignancies in different neuroendocrine systems and higher incidents in the GI and Non-GI tract of SST analogs have been confirmed in antiseretary and antinumor efficacy (19, 68–70, 74, 78, 83). The FDA approved peptide-receptor radionuclide therapy (Lutathera®) for gastroenteropancreatic NETs; the treatment can improve patient survival (71, 79). This mini review presents the current drugs used in basic and clinical practice (Table 2). Anti-SSTR2 antibody drugs have been developed for NET diagnosis and therapy (79, 80). Small molecule SSTR4 agonists (4-phenetylamino-7H-pyrrolo[2,3-d] pyrimidine derivatives, 100µg/kg, oral) inhibited neurogenic inflammation and peristalsis (6, 16, 29, 70, 78) and showed anti-tumor effects in solid tumor or cancer (29, 71, 79). Escalated doses of SST analogs (Octreotide, >30mg or Lanreotide, >120mg/d, 28days) were well tolerated with antiproliferative effects in neuroendocrine neoplasms (NEN) patients (72). Recently, phosphate-specific antibodies have shown agonist-selective properties for individual tumor tissues (75). NET patients overexpressed SSTR2 at high density; the membrane expression of SSTR2 in tumors cells is ~20-fold higher than that of normal cells (79, 84). Immunohistochemistry analysis showed over 70% of NET patients

| Function | Gastrointestinal system | Neuroendocrine and endocrine tissue | References |
| --- | --- | --- | --- |
| Name | Secretion | Movement | Blood vessel | Inflammation | Proliferation (Tumor/cancer) |
| **SST (analogues)** | | | | | |
| Octreotide (Sandostatin) | ↓ (gastric juice, gastric acid) | ↓ (gastric emptying, segmental motility) | ↓ | ↓ | ↓ normal tissue and tumor, Severe diarrhea, Carcinoid syndrome with unresectable, metastasized tumor | (11, 16, 29, 68–72) |
| Lanreotide | ↓ | ↓ mass peristalsis | ↓ | ↓ | ↓ normal tissue and tumor, For imaging in nuclear medicine | (16, 19, 29, 70, 73, 74) |
| Pasireotide | ↓ | ↓ defecation reflex | ↓ | ↓ | ↓ | (6) |
| Cortistatin | ↓ | ↓ | ↓ | ↓ | ↓ | (6) |
| Somatoprim (heptapeptide) | ↓ | ↓ | ↓ | ↓ | ↓ | (6) |
| In-111-Pentetreotide | ↓ | ↓ | ↓ | ↓ | ↓ | (6) |
| SST receptor phosphorylation or dephosphorylation (agonist) | C-terminal serine/threonine | ↓ | ↓ | ↓ | ↓ | (6, 75, 77) |
| Chimeric molecule, Combination (+agonist or antagonist) | +DA receptor 2 (D2DR) | ↓ | ↓ | ↓ | ↓ | (75) |
| Dopastatin | ↓ | ↓ | ↓ | ↓ | ↓ | (69–71, 78) |
| +GH receptor (pegvisomant) | ↓ | ↓ | ↓ | ↓ | ↓ | (29, 71, 79) |
| +mTOR inhibitor (rapamycin, everolimus) | ↓ | ↓ | ↓ | ↓ | ↓ | (6) |
| Antibody for human SST 2/5 receptors | | | | | | |
| Combination (+chem-molecules) | +α interferon (tamoxifen) | ↓ | ↓ | ↓ | ↓ | (11, 78) |
| +anti-VEGF (bevacizumab) | ↓ | ↓ | ↓ | ↓ | ↓ | (22, 72, 79) |

**GPCR, G protein-coupled receptor; R1-R5, receptor 1-5; DA, Dopamine; D2DR, D2 of dopamine receptor; VEGF, Vascular endothelial growth factor; Gαi;q, subtype of G proteins; mTOR, Mammalian target of rapamycin; GH, Growth hormone; GI, Gastrointestinal tract;↓ = Downregulation; = Unchanged.**

**Table 2**

Effect of SST and SSTRs in the gastrointestinal system for basic research and clinical medicine.
with expressed-SSTR2 (79, 84). SSTR expression is a biomarker of NEN biology and immunohistochemical staining SST, while SSTR and CGA are candidates for prognostic information and risk-stratification in clinic. SSTR2a was a positive prognostic marker for pancreatic NEN (79, 85). Monitoring of treatment of SST analogues and changed-circulating CGA levels can predict disease recurrence, outcome, and efficacy (29). It is very interesting that the image for SST-SSTRs showed nonspecific accumulation in activated immunological cells, lymphocytes, epithelioid cells, monocytes, and blood vessels (76). Internalization of the radiolabeled agonist was mandatory for SSTR-mediated imaging and therapy, but radiolabeled SSTR antagonists might perform better in preclinical work (86). SST (0.25mg, and prophylactically SST long-term (0.25mg/h for 10h iv) decreased post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and post-ERCP hyperamylasemia (87). However, current effective preventive strategy suggested rectal non-steroidal anti-inflammatory drugs and pancreatic stent placement (88), and a meta-analysis showed SST lacks the benefit in patients with ERCP after short-term infusion, but gains an advantage in single-bolus or long-term injection (89). Therefore, the risk vs benefit of SST and analogues should be carefully assessed in patients (88). Long-acting SST analogues (Octreotide, 20mg/m or Lanreotide, 90mg/28 d, 12months, im) decreased blood but gains an advantage in single-bolus or long-term injection (89).

CONCLUSION

SST-endoctrine cells and neurons are a critical effector to maintain homeostasis via SSTRs 1-5 and co-receptors. SST-SSTRs are involved in chemo-sensory, secretion, motility, and inflammation responses by autocrine, paracrine, endocrine, and exendocrine pathways. SST is also a powerful inhibitor for tumor cell proliferation, severe inflammation, and perioperation, and is listed as a first-line anti-cancer drug in clinical practice. New development prognostic SS-SSTRs-markers, phosphate-specific antibodies, and molecular imaging have emerged in diagnostics and therapy. Dis-inhibition and network of SST-SSTRs in the PNS of the sympathetic and parasympathetic nerve system and special DRG should be explored. Understanding the mechanisms of neuroendocrine in SST-SSTRs in the GI will provide an insight into advanced medicine.

AUTHOR CONTRIBUTIONS

BHS, MC, and XQC drafted the manuscript. XQC supervised the project and conceived of the study. XXK contributed to discussion and manuscript editing. XX contributed to Table 2. All authors contributed to the article and approved the submitted version.

FUNDING

This research was supported by the National Natural Science Foundation of China (grant number 81930054, grant number 81741120) and the Ministry of Science and Technology of China, National Basic Research Program (973) of China (grant number 2012CB518200).

REFERENCES

1. Yavorska I, Wehr M. Somatostatin-expressing inhibitory interneurons in cortical circuits. Front Neural Circuits (2016) 10:76. doi: 10.3389/fncir.2016.00076
2. Urban-Ciecko J, Barth AL. Somatostatin-expressing neurons in cortical networks. Nat Rev Neurosci (2016) 17:401–9. doi: 10.1038/nrn.2016.53
3. Saiz-Sanchez D, Ubeda-Bañón I, Flores-Cuadrado A, Gonzalez-Rodriguez M, Villar-Conde S, Astillero-Lopez V, et al. Somatostatin, octation, and neurodegeneration. Front Neurosci (2020) 14:966/96. doi: 10.3389/fnins.2020.00096
4. Kossut M, Łukomska A, Dobrzan A, Górecki L, Zięba A, Zięba D, et al. Somatostatin receptors in the brain. Postepy Biochem (2018) 64:213–21. doi: 10.18388/pb.2018_133
5. Gokonowski S, Rydel L. Somatostatin as an active substance in the mammalian enteric nervous system. Int J Mol Sci (2019) 20:4661. doi: 10.3390/ijms20014661
6. Günter T, Tulipano G, Dourmad P, Bousquet C, Casba Z, Kreienkamp HJ, et al. International union of basic and clinical pharmacology. Cv. Somatostatin receptors: Structure, function, ligands, and new nomenclature. Pharmacol Rev (2018) 70:763–835. doi: 10.1124/pr.117.015388
7. Morisset J, Somatostatin. One of the rare multifunctional inhibitors of mammalian species. Pancreas (2017) 46:18. doi: 10.1097/MPA.0000000000000716
8. Schubert ML, Rehfeld JF. Gastric peptides-gastrin and somatostatin. Compr Physiol (2019) 10:197–228. doi: 10.1002/cphy.c180035
9. Engevik AC, Kaji I, Goldenring JR. The physiology of the gastric parietal cell. Physiol Rev (2020) 100:573–602. doi: 10.1152/physrev.00016.2019
10. Rorsman P, Huising MO. The somatostatin-secreting pancreatic β-cell in health and disease. Nat Rev Endocrinol (2018) 14:404–14. doi: 10.1038/s41574-018-0020-6
11. Reynaert H, Colle I. Treatment of advanced hepatocellular carcinoma with somatostatin analogues: A review of the literature. Int J Mol Sci (2019) 20:4811. doi: 10.3390/ijms20194811
12. Brighi N, Lamberi G, Maggio I, Manuzzi L, Ricci C, Casadei R, et al. Bilary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. Dig Liver Dis (2019) 51:689–94. doi: 10.1016/j.dld.2018.09.013
13. Lewin AE, Vecino S, Richardson J, Dretchen KL, Gillis RA, Sahibzada N. Optogenetic and pharmacological evidence that somatostatin-gaba neurons are important regulators of parasympathetic outflow to the stomach. J Physiol (2016) 594:2661–79. doi: 10.1111/jpp.12706
14. Stengel A, Taché YF. Activation of brain somatostatin signaling suppresses crf receptor-mediated stress response. Front Neurosci (2017) 11:231. doi: 10.3389/fnins.2017.00231
15. Robinson SL, Thiele TE. A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders. Neuropharmacology (2020) 167:107983. doi: 10.1016/
jneuropharm.2020.107983

16. Sun L, Coy DH. Somatostatin and its analogs. Curr Drug Targets (2016) 17:529–37. doi: 10.2174/1389450116666141205163548

17. Egerod KL, Engelstoft MS, Lund ML, Grunddal KV, Zhao M, Barir-Jensen D, et al. Transcriptional and functional characterization of the g protein-coupled receptor repertoire of gastric somatostatin cells. Endocrinology (2015) 156:3909–23. doi: 10.1210/en.2015-1513

18. Kecskés A, Pohóczky K. Characterization of neurons expressing the novel analgesic drug target somatostatin receptor 4 in mouse and human brains. Int J Mol Sci (2020) 21:7788. doi: 10.3390/ijms2107788

19. Newell Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR, et al. Use of late-night salivary cortisol to monitor response to medical treatment in cushing’s disease. Eur J Endocrinol (2020) 182:207–17. doi: 10.1530/eje-19-06965

20. Bulc M, Palus K, Calka J. The influence of a hyperglycemic condition on the population of somatostatin enteric neurons in the porcine gastrointestinal tract. Animals (2020) 10:142. doi: 10.3390/anim0100142

21. Palus K, Bulc M, Calka J. Changes in somatostatin-like immunoreactivity in the sympathetic neurons projecting to the prepyloric area of the porcine stomach induced by selected pathological conditions. BioMed Res Int (2017) 2017:9037476. doi: 10.1155/2017/9037476

22. Corleto VD. Somatostatin and the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes (2010) 17:63–8. doi: 10.1097/MED.0b013e328333463ed

23. Vanheule E, Geerts AM, Reynaert HS, Calka J, De Wever H, Pardon D, et al. Influence of somatostatin and octreotide on liver microcirculation in an experimental mouse model of cirrhosis studied by intravital fluorescence microscopy. Liver Int (2008) 28:107–16. doi: 10.1111/j.1478-3231.2007.01629.x

24. Chera S, Baronnier D, Ghila L, Cigilova V, Jensen JN, Gu G, et al. Diabetes recovery by age-dependent conversion of pancreatic β-cells into insulin producers. Nature (2014) 514:503–7. doi: 10.1038/nature13633

25. Iwamaga T, Miya T, Takahashi-Iwamaga H. Restricted expression of somatostatin receptor 3 to primary cilia in the pancreatic islets and adenohypophysis of mice. Biomed Res Int (2011) 32:73–81. doi: 0.1220/biomedres.32.73

26. Prevot TD, Gastambide F, Viollet C, Henkous N, Martel G, Epelbaum J, et al. Roles of hippocampal somatostatin receptor subtypes in stress response and emotionality. Neuropharmacology (2017) 122:1647–56. doi: 10.1016/j.nphar.2016.281

27. Yamamoto M, Ben-Shlomo A, Kameda H, Fukuoka H, Deng N, Ding Y, et al. Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function. JCI Insight (2018) 3(19):e122932. doi: 10.1172/jci.insight.122932

28. Alshafie W, Franchi V, Bednarz K, Pan YE, Stroth T, McPherson PS. Resurfacing of a somatostatin receptor storage compartment fine-tunes pituitary secretomotor function. Endocrinology (2019) 160:1511–20. doi: 10.1210/endo.2019-00549

29. Lepsen SL, Grunddal KV, Weyer Albrechtsen NJ, Engelstoft MS, Gabe MB, Jensen EP, et al. Paracrine crosstalk between intestinal l and d-cells controls secretion of glucagon-like peptide-1 in mice. Am J Physiol Endocrinol Metab (2019) 317:E1081–93. doi: 10.1152/ajpendo.00239.2019

30. Terry NA, Ngaba LV, Wilkins BJ, Pi D, Gheevela N, Kaestner KH. Lipid malabsorption from altered hormonal signaling changes early gut microbial responses. Am J Physiol Gastrointestinal Liver Physiol (2018) 315:G580–91. doi: 10.1152/ajpgi.00135.2018

31. Zhang J, Chen B, Liu B, Zhou X, Mu J, Wang Q, et al. Preventive effect of lactobacillus fermentum cgc53 on activated carbon-induced constipation in iri mice. Medicina (2018) 54:89. doi: 10.3390/medicina5400508

32. Yang Y, Wu X, Wei Z, Dou Y, Zhao D, Wang T, et al. Oral curcumin has anti-arthritis efficacy through somatostatin generation via camp/pka and ca2+ signaling pathways in the small intestine. Pharmacol Res (2015) 95:71–81. doi: 10.1016/j.phrs.2015.03.016

33. Wixner J, Törnblom H, Karlén P, Anan I, Lindberg G. Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis. Neurogastroenterol Motil (2015) 30:e13354. doi: 10.1111/nmo.13354

34. El-Salhy M, Umezawa K. Treatment with novel ap-1 and nf-kb inhibitors restores the colonic endocrine cells to normal levels in rats with dss-induced colitis. Int J Mol Med (2016) 37:556–64. doi: 10.3892/ijmm.2016.2481

35. El-Salhy M, Hatlebakk JG. Changes in enterocyte and immune cells following colitis induction by trbs in rats. Mol Med Rep (2016) 14:4967–74. doi: 10.3892/mmr.2016.5902

36. Li X, Cai L, Xu H, Geng C, Lu J, Tao L, et al. Somatostatin regulates nh8 protein expression via the ekr1/2 mapk pathway in dss-induced colitis mice. Am J Physiol Gastrointestinal Liver Physiol (2016) 311:G954–63. doi: 10.1152/ajpgi.00239.2016

37. Song S, Li X, Geng C, Li Y, Wang C. Somatostatin stimulates colonic muc2 expression through sirt5-notch-hes1 signaling pathway. Biochem Biophys Res Commun (2020) 521:1070–6. doi: 10.1016/j.bbrc.2019.11.034

38. Lennicke C, Rahn J, Wickenhauser C, Lichtenfels R, Müller AS, Wessjohann LA, et al. Loss of epithelium-specific gpx2 results in aberrant cell fate decisions during intestinal differentiation. Oncotarget (2018) 9:539. doi: 10.18632/oncotarget.22640

39. Billing LJ, Larraufie P, Lewis J, Leiter A, Li J, Lam B, et al. Single cell transcriptomic profiling of large intestinal enterocyte cells in mice—identification of selective stimuli for insulin-like peptide-5 and glucagon-like peptide-1 co-expressing cells. Mol Metab (2019) 29:158–69. doi: 10.1016/j.molmet.2019.09.001

40. Mazzawi T, Hausken T, Gundersen D, El-Salhy M. Dietary guidance normalizes large intestinal enterocyte cell densities in patients with irritable bowel syndrome. Eur J Clin Nutr (2016) 70:170–81. doi: 10.1038/ejcn.2015.191
65. Furuyama K, Chera S, Van Gurp L, Oropeza D, Ghila L, Damond N, et al.
64. Vergari E, Knudsen JG, Ramracheya R, Salehi A, Zhang Q, Adam J, et al.
63. Denwood G, Tarasov A, Salehi A, Vergari E, Ramracheya R, Takahashi H,
61. Chen XQ, Xu NY, Du JZ, Wang Y, Duan CC. Corticotropin-releasing factor
60. Xu NY, Chen XQ, Du JZ, Wang TY, Duan C. Intermittent hypoxia causes a
57. Löhr H, Hess S, Pereira MM, Reinoß P, Leibold S, Schenkel C, et al. Diet-
53. Mazzawi T, El-Salhy M. Changes in duodenal enteroendocrine cells in
55. Ji R, Zhu J, Wang D, Sui Q-Q, Knight GE, Burnstock G, et al. Expression of
73. Couvelard A, Colao A, Grassi LF, Giustina A, Melmed S, Chanson P, et al. Acromegaly. Nat Rev Dis Primers (2019) 5:20. doi: 10.1038/s41572-019-0071-6
71. Öberg K, Lamberts SW. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: Past, present and future. Endocrine-Related Cancer (2016) 23:R531–66. doi: 10.1530/ERC-16-0151
72. Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S, Escalated-dose somatostatin analogues for antiproliferative effect in genotypical adenocarcinoma of the pancreas: a systematic review. Endocrine (2017) 57:366–75. doi: 10.1007/s12020-017-1360-9
73. Couvelard A, Pelaprat D, Dokmal S, Sauvanet A, Voisin T, Couverine A, et al. Antisecretory effects of chimeric somatostatin/dopamine receptor ligands on gastroenteropancreatic neuroendocrine tumours. Pancreas (2017) 46:631–8. doi: 10.1097/MPA.0000000000000813
74. Colao A, Petersen S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-month phase 3 study of pasireotide in cushing’s disease. N Engl J Med (2014) 371:1194–41. doi: 10.1056/NEJMoa105743
75. Schulz S, Lehmann A, Kliwer A, Nagel F. Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: luphar review 5. Br J Pharmacol (2014) 171:1591–9. doi: 10.1111/bph.12551
76. Bhanet N, Koeh CA, Parmar R, Garla V, Vijaykumar V. Somatostatin receptor expression in non-classical locations - clinical relevance? Rev Endocr Metab Disord (2018) 19:123–32. doi: 10.1007/s11514-018-9470-3
77. Anzola LK, Rivera JN, Dierckx RA, Lauri C, Valabrega S, Galli F. Value of somatostatin receptor scintigraphy with (99m)tc-hynic-toc in patients with primary sirogren syndrome. J Clin Med (2019) 8:673. doi: 10.3390/jcm8060763
78. Gomes-Porras M, Cárdenas-Salas J. Somatostatin analogs in clinical practice: A review. Int J Mol Sci (2020) 21:1682. doi: 10.3390/jm21051682
79. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin (2018) 68:471–87. doi: 10.3322/caac.21493
80. Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K, et al. Anti-sstr2 antibody-drug conjugate for neuroendocrine tumor therapy. Cancer Gene Ther (2020), 1–14. doi: 10.1038/s41417-020-0196-5
81. Herrera-Martínez AD, van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Culler MD, de Herder WW, et al. Effects of novel somatostatin-dopamine chimeric drugs in 2d and 3d cell culture models of neuroendocrine tumors. Endocr Relat Cancer (2019) 26:385–99. doi: 10.1530/erc-190086
82. Fernández Vargas S, Kossatz S, Voisi J, Ghosh SC, Tran Cao HS, Smien I. Specific targeting of somatostatin receptor subtype-2 for fluorescence-guided surgery. Clin Cancer Res (2019) 25:4332–42. doi: 10.1158/1078-0432-ccr-18-3312
83. Vergès B. Effects of anti-somatostatin agents on glucose metabolism. Diabetes Metab (2017) 43:411–5. doi: 10.1688/diabete.2017.05.003
84. Brunner P, Jörg A-C, Glatz K, Bubendorf L, Radojewski P, Ullmair M, et al. The prognostic and predictive value of sstr 2-immunohistochemistry and sstr 2-targeted imaging in neuroendocrine tumors. Eur J Mol Med Imaging (2017) 44:468–75. doi: 10.1007/s00259-016-0348-2
85. Nielsen K, Binderup T. PS3 somatostatin receptor 2a and chromogranin a immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms. BMC Cancer (2020) 20:267. doi: 10.1186/s12885-019-6498-2
86. Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Natl Med (2017) 58:616–6s. doi: 10.2967/jnumed.116.186783
87. Wang G, Xiao G, Xu L, Qiu P, Li T, Wang X, et al. Effect of somatostatin on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia: A systematic review and meta-analysis. Panreatology (2018) 18:370–8. doi: 10.1016/j.pan.2018.03.002
88. Bhatt H. Post-endoscopic retrograde cholangiopancreatography pancreatitis: an updated review of current therapeutic strategies. Clin Exp Gastroenterol (2021) 14:237–32. doi: 10.2147/CEG.S276361
89. Qin X, Lei WS, Xing ZX, Shi F. Prophylactic effect of somatostatin in preventing Post-ERC pancreatitis: an updated meta-analysis. Saudi J Gastroenterol (2021) 25:372–8. doi: 10.4103/1319-3767.167187
90. Bon C, Aparicio T, Vincent M, Mavros M, Bejou B, Raynaud JJ, et al. Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodyplasia. Aliment Pharmacol Ther (2012) 36:587–93. doi: 10.1111/j.1365-2036.2010.04808.x
91. Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca A, Barriuso J, Cañasto Á, Benavent M, et al. Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: The GETNE-TRASGU study. J Clin Oncol (2019) 37:2571–80. doi: 10.1200/jco.19.00980
92. Jiménez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Cañasto A, Benavent M, et al. External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: The GETNE-TRASGU study. Neuroendocrinology (2021). doi: 10.1159/000514808
93. Lamberti G, Faggiano A, Bright N, Tafuro S, Ibrahim T, Brizi MP, et al. Nonconventional doses of somatostatin analogs in patients with progressing neuroendocrine tumors. J Clin Endocrinol Metab (2020) 105 (1):194–200. doi: 10.1210/clinem/dgaz072
94. Haris B, Saraswathi S, Hussain K. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia. Ther Adv Endocrinol Metab (2020) 11:202018820965068. doi: 10.1177/204218820965068
95. McMahon AW, Wharton GT, Thornton P, De Leon DD. Octreotide use and safety in infants with hyperinsulinism. *Pharmacoepidemiol Drug Saf* (2017) 26:26–31. doi: 10.1002/pds.4144

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.